Patheon expands into India through Kemwell alliance
Patheon, a global provider of drug development and manufacturing services to the pharma industry with European headquarters in Switzerland, has entered into an agreement with Kemwell, an Indian manufacturer of tablets, capsules, liquid orals, external drops, ointments, gels and creams based in Bangalore.
Patheon, a global provider of drug development and manufacturing services to the pharma industry with European headquarters in Switzerland, has entered into an agreement with Kemwell, an Indian manufacturer of tablets, capsules, liquid orals, external drops, ointments, gels and creams based in Bangalore.
According to Wes Wheeler, president and chief executive of Patheon, the alliance gives the company more flexibility in its service offering.
"With Kemwell's GMP facility and expertise, we can offer our clients low volume, low cost solutions in solid, semi-solid and liquid dosage form manufacturing, and a full range of formulation and CMC-related development services from a new base in India," he said.
"Patheon's aseptic and high-potent manufacturing expertise brings an important capability to Kemwell's portfolio of services," said Anurag Bagaria, vice-president of business development at Kemwell.